Coulter Partners Places Industry Veteran Mark Rothera as CEO of TreeFrog Therapeutics

TreeFrog Therapeutics is a French regenerative medicine biotech focused on providing mass access to cell therapies. By combining biophysics and engineering, they produce high-quality cells at unprecedented scale and cost-effectiveness through internal programs and strategic partnerships.

Mark Rothera has built a strong reputation, driving the successful scale up of multiple biotech companies, including most recently, Viracta, Silence Therapeutics and Orchard Therapeutics. Renowned for building strong leadership teams that advance novel medicines through development to regulatory approval and commercialization, Mark has focused much of his career on specialty diseases and novel modalities including gene therapy and RNAi therapies. In his earlier career, he held commercial lead roles in PTC Therapeutics, Aegerion, Shire, and GSK.

Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented: “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver programs, further strengthen our regenerative medicine platform and pursue strategic partnerships such as the one in place with Vertex for their Type 1 Diabetes pipeline.”

Elsy Boglioli added: “Finding a CEO who could bridge both European and US business cultures was a primary objective for us, and Coulter Partners was instrumental in navigating this complex requirement. Their global perspective and deep understanding of our unique mission allowed them to identify the perfect candidate who fits our specific cultural and strategic needs. We appreciated their diligent approach and expertise in delivering such a high-impact leadership placement as we enter our next phase of international growth.”

Nicolas Leray, Associate Partner at Coulter Partners added: “We were delighted to partner with TreeFrog during this pivotal leadership transition. This assignment is a testament to the excellence and collaborative approach of our teams on both sides of the Atlantic, which enables us to conduct seamless, simultaneous searches in the U.S. and Europe. We look forward to the impact Mark will undoubtedly have on TreeFrog’s next chapter.”

---

Mark Rothera, CEO TreeFrog Therapeutics

Mark brings more than 35 years of experience in the biopharmaceutical industry, with a strong record of driving the successful scaling of multiple biotech companies in both private and public settings. TreeFrog marks his fourth CEO role. He most recently served as President and CEO of Viracta (Nasdaq: VIRX) and previously led Silence Therapeutics (Nasdaq: SLN), a clinical-stage RNAi platform company.

Mark’s first CEO role was with Orchard Therapeutics (Nasdaq: ORTX), where he oversaw its transformation from a UK-based startup into a leading transatlantic public gene therapy company. Prior to this, he served as Chief Commercial Officer of PTC Therapeutics (Nasdaq: PTCT) and held senior leadership positions at Aegerion Pharmaceuticals and Shire Human Genetic Therapies. Mark received an M.A. in Natural Sciences from Cambridge University and an M.B.A. from INSEAD.

About TreeFrog Therapeutics

About Coulter Partners